|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
2.200 USD |
+8.37% | +14.58% | -77.37% | |
April 28, 2025 at 12:00 am EDT
Effective April 28, 2025, INVO Fertility, Inc. will change its Nasdaq Capital Market stock ticker symbol to IVF from NAYA.
|
INVO Fertility, Inc. will Change its Ticker to IVF from NAYA |
12:00am |
CI |
|
NAYA Biosciences Renames Itself INVO Fertility; Separates Oncology, Fertility Businesses |
Apr. 15 |
MT |
|
INVO Fertility Plans to Divest A Majority Stake in Naya Therapeutics |
Apr. 14 |
CI |
|
NAYA Biosciences, Inc. has Changed its Name to INVO Fertility, Inc |
Apr. 14 |
CI |
|
Naya Biosciences Inc – Regains Compliance With Nasdaq Listing Rule – SEC Filing |
Mar. 31 |
RE |
|
Naya Biosciences Announces Development of Ny-500, A Novel Ai-Optimized Pd-1 X Vegf Bifunctional Antibody |
Jan. 06 |
CI |
|
NAYA Biosciences, Inc. Announces Executive and Board Appointments |
Dec. 12 |
CI |
|
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma |
24-10-24 |
CI |
|
NAYA Biosciences, Inc.(NasdaqCM:NAYA) added to NASDAQ Composite Index |
24-10-22 |
CI |
|
INVO Bioscience, Inc.(NasdaqCM:INVO) dropped from NASDAQ Composite Index |
24-10-21 |
CI |
|
INVO Bioscience, Inc. Announces Board Changes |
24-10-15 |
CI |
|
INVO BioScience, Inc. has Changed its Name to NAYA Biosciences, Inc |
24-10-15 |
CI |
|
INVO BioScience, Inc. has Changed its Ticker to NAYA from INVO |
24-10-15 |
CI |
|
INVO Bioscience Completes Merger With NAYA Biosciences Acquisition |
24-10-14 |
MT |
|
NAYA Biosciences completed the acquisition of INVO Bioscience, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction. |
24-10-13 |
CI |
|
Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Loss $-0.62 Per Share |
24-08-14 |
MT |
|
Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Revenue $1.8M |
24-08-14 |
MT |
|
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-14 |
CI |
|
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 |
24-05-15 |
CI |
|
Top Premarket Decliners |
24-04-18 |
MT |
|
Sector Update: Health Care Stocks Retreating Late Afternoon |
24-04-17 |
MT |
|
Top Midday Gainers |
24-04-17 |
MT |
|
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly |
24-04-17 |
MT |
|
Top Premarket Gainers |
24-04-17 |
MT |
|
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 |
24-04-16 |
CI |
NAYA: Dynamic Chart
NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
More about the company
Annual profits – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
